We are dedicated to developing and commercializing innovative vaccines that modulate the immune system to prevent disease.
About Dynavax Technologies
Dynavax Technologies Corporation (Nasdaq: DVAX) is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation. Dynavax develops, and commercializes novel vaccines.
We are committed to a rigorous approach to drug development in the field of TLR biology so that we may help physicians and patients address unmet needs. Our vision and work ethic are guided by the collective ideals underpinning our corporate values, and these form the basis of our company culture.
Our management team is comprised of industry veterans that have extensive expertise in drug development and commercialization. With experience spanning successful biopharmaceutical companies to pertinent government organizations, they bring a rich knowledge-base to lead a growing fast-paced company.
Steven N. Gersten
Senior Vice President, General Counsel, Chief Ethics and Compliance Officer and Secretary
Steven N. Gersten is Senior Vice President, General Counsel, Chief Ethics and Compliance Officer, and Secretary of Dynavax. He joined Dynavax in 2015 as Vice President, General Counsel, and Chief Ethics and Compliance Officer. Prior to joining Dynavax, he served as global Vice President and Ethics and Compliance Officer at AbbVie, where he helped build the compliance program and organization. From 2002 to 2013, he was employed by Abbott Laboratories, where he served as global Vice President and Chief Regulatory and Compliance Counsel, and global Vice President and Chief Counsel / General Counsel to several business units, setting global legal strategies and functional plans as well as overseeing the internal legal organization and external counsel. Prior to joining Abbott, Mr. Gersten held various positions of increasing responsibility with the U.S. Department of Justice (where he brought enforcement cases on behalf of the FDA), the law firms Howrey and Simon, and Shea and Gould, and with the U.S. Attorney’s Office in Washington, D.C. Mr. Gersten holds a JD degree from the Boston University School of Law and a BS degree with a concentration in Finance from the Boston University Questrom School of Business.
Chief Medical Officer and Senior Vice President, Clinical Development
Dr. Janssen was appointed Chief Medical Officer and Vice President, Clinical Development in July 2013. He previously served as Dynavax's Vice President, Medical Affairs and Senior Director, Clinical Development. Prior to joining Dynavax in 2010, Dr. Janssen was Vice President, Medical Affairs at Gilead from 2008 to 2010 where he was responsible for oversight of physician and health care provider education focused on HIV and hepatitis B therapies. Until 2008, Dr. Janssen spent 23 years at the US Centers for Disease Control and Prevention (CDC), most recently as the Director of the Division of HIV/AIDS Prevention from 2000 to 2008. Under his leadership, CDC first explored HIV treatment as a mode of HIV prevention and launched several of the earliest Phase 3 trials of pre-exposure prophylaxis for HIV. Dr. Janssen received a Bachelor of Arts degree with Honors in Humanities from Stanford University and his M.D. degree from the University of Southern California. He is a neurologist with training in virology at the University of Pennsylvania. Dr. Janssen has been the beneficiary of numerous honors and awards during his career. He has published over 130 scientific articles in a variety of journals and has served as a reviewer for leading scientific journals.
Senior Vice President, Operations and Quality, CO-PRESIDENT
Mr. Novack has been the Senior Vice President of Operations for Dynavax since 2013, and has led the company’s technical operations, supply chain, and quality teams through FDA approval, launch and commercialization of HEPLISAV-B. Mr. Novack has more than 30 years of relevant industry experience, with more than 20 years of direct vaccine industry experience. Prior to Dynavax, Mr. Novack was at Novartis where he served in various roles, including Global Head of Technical Operations and Supply Chain for Diagnostics, and Global Head of Manufacturing Strategy for Vaccines. Prior to Novartis, Mr. Novack held management positions at MedImmune and Lederle Laboratories (now Pfizer). Mr. Novack received a B.S. in Biology from the State University of New York at Albany, and an M.B.A. from Columbia University.
Michael S. Ostrach
Senior Vice President, Chief Financial Officer and Chief Business Officer
Mr. Ostrach joined Dynavax in 2006 as Vice President, Chief Business Officer and General Counsel and became Principal Financial Officer in 2013 and Chief Financial Officer in 2015. From 2005 to 2006, he was Chief Operating Officer, Chief Financial Officer and General Counsel at Threshold Pharmaceuticals. From 1997 to 2004, Mr. Ostrach was at Kosan Biosciences, most recently as President and Chief Operating Officer. Mr. Ostrach began his corporate career at Cetus Corporation, where he served in several capacities between 1981 and 1991, initially as general counsel and finally as Senior Vice President of corporate affairs and General Counsel. Following the acquisition of Cetus by Chiron Corporation in 1991, Mr. Ostrach became President of Chiron Technologies. He holds a B.A. from Brown University and a J.D. from Stanford Law School.
SENIOR VICE PRESIDENT OF COMMERCIAL, CO-PRESIDENT
Ryan Spencer, joined Dynavax in 2005 and currently serves as the Senior Vice President of Commercial. Throughout his time at Dynavax, Mr. Spencer has held a variety of positions with increasing responsibility, building from a foundation in corporate finance to business strategy and investor relations, culminating in his current role leading the launch and commercialization of HEPLISAV-B. Prior to joining Dynavax, Mr. Spencer was the Assistant Controller at QRS Corporation, a publicly-held technology company, and was a member of the audit practice at Ernst & Young. Mr. Spencer earned a B.A. in Business Economics from University of California, Santa Barbara.
Senior Vice President, Human Resources and Corporate Services
Mr. Coon joined Dynavax in 2019 as Senior Vice President, Human Resources and Corporate Services. From 2017 to 2019, he was the Senior Vice President of Human Resources at FivePrime Therapeutics. From 2011 to 2017, Mr. Coon was at Depomed, Inc., where he served as Senior Vice President, Human Resources and Administration. Mr. Coon has held senior-level Human Resources positions with several life sciences companies over his thirty plus year career, including Johnson & Johnson, PDL BioPharm and Exelixis. He received a M.S. in Human Resources Management from Golden Gate University and a B.A. in Public Administration from the California State University-Long Beach.
Our Board of Directors is a pedigreed group with broad leadership backgrounds. Their current and previous roles as biotech executives, physicians, researchers, and investors provides us with multifaceted expertise to help us reach our shared vision for helping patients.
Arnold L. Oronsky, Ph.D.
Chairman of the Board
Dr. Oronsky has been a member of the Dynavax board since November 1996 and became Chairman in February 2006. Dr. Oronsky is a managing director with InterWest Partners, a venture capital firm. Prior to joining InterWest Partners in 1994, Dr. Oronsky was Vice President of Discovery Research for the Lederle Laboratories division of American Cyanamid, a pharmaceutical company. From 1973 until 1976, Dr. Oronsky was head of the inflammation, allergy and immunology research program at Ciba-Geigy Pharmaceutical Company. Dr. Oronsky also serves as a senior lecturer in the Department of Medicine at The Johns Hopkins Medical School. Dr. Oronsky has won numerous grants and awards and has published over 125 scientific articles. He received his Ph.D. from Columbia University, College of Physicians and Surgeons and his A.B. from New York University.
Ms. Brege has been a member of the Dynavax board since February 2015. She is President and Chief Executive Officer of Nodality Inc. She has over 20 years of executive management experience in the pharmaceutical, biotechnology and venture capital industries. Prior to joining Nodality in 2012, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., including Executive Vice President and Chief Operating Officer. While at Onyx she led multiple functions, including commercialization, strategic planning, corporate development, and medical, scientific and government affairs. Prior to Onyx, Ms. Brege was a General Partner at Red Rock Capital Management, a venture capital firm specializing in early stage financing for technology companies. Previously Ms. Brege was SVP and Chief Financial Officer at COR Therapeutics, helping build the company from an early stage R&D company through commercial launch of a successful cardiovascular product. Earlier in her career, she served as Chief Financial Officer at Flextronics, Inc. and Treasurer of The Cooper Companies. She serves on the Board of Directors of Acadia Pharmaceuticals, Inc., Aratana Therapeutics, Inc. and Pacira Pharmaceuticals, Inc. Ms. Brege earned her undergraduate degrees from Ohio University (Honors Tutorial College) and her MBA degree from the University of Chicago.
Francis R. Cano, Ph.D.
Dr. Cano was appointed to the Dynavax board in November 2009. Dr. Cano is President and Founder of Cano Biotech Corp., a consulting firm focusing on the vaccine business, and also serves on the boards of Biomerica, Inc., a developer and manufacturer of diagnostic products, and Arbor Vita Corporation, a biopharmaceutical company. From 1993 to 1996, Dr. Cano was President and Chief Operating Officer for Aviron, a biopharmaceutical company, which was later acquired by MedImmune in 2001. As a Co-Founder of Aviron, he completed two rounds of venture financing, a licensing agreement with SmithKline Biologicals and in-licensed Flu-Mist influenza vaccine from the National Institutes of Health. For 21 years, Dr. Cano worked with the Lederle Laboratories Division of American Cyanamid, most recently as Vice President and General Manager of the Biologicals unit. He earned a Ph.D. in Microbiology from Pennsylvania State University, served as a Research Associate at Rutgers Institute of Microbiology, and holds a M.S. in Microbiology and a B.S. in Biology from St. John's University.
Dennis A. Carson, M.D.
Dr. Carson has been a member of the Dynavax board since December 1997. Dr. Carson is a noted researcher in the fields of autoimmune and immunodeficiency diseases and is co-discoverer with Dr. Eyal Raz of the immunostimulatory sequences (ISS) that form the basis of our technology. He has played key roles in the founding of Vical, Inc., a gene therapy company, IDEC Pharmaceuticals, a biopharmaceutical company, and Triangle Pharmaceuticals, a pharmaceutical company. Dr. Carson is a director of Biomerica, Inc. Dr. Carson is director of the Rebecca and John Moores Cancer Center at the University of California, San Diego and has been a professor in the Department of Medicine at the University of California, San Diego since 1990. He is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the Institute of Medicine, as well as the American Association for Cancer Research, the American Society for Clinical Investigation, the American Society of Hematology and the Association of American Physicians. He received his M.D. from Columbia University and his B.A. from Haverford College. Dr. Carson completed his residency in internal medicine and a postdoctoral fellowship at the University of California, San Diego.
Andrew Hack, M.D., Ph.D.
Dr. Hack has been a member of the Dynavax board since August 2019. Dr. Hack is a Managing Director at Bain Capital Life Sciences, a private equity fund that invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics, and enabling life science technology companies globally. Dr. Hack served as Chief Financial Officer of Editas Medicine, Inc. (NASDAQ: EDIT), from July 2015 to March 2019. Prior to joining Editas, he was a portfolio manager at Millennium Management LLC, an institutional asset manager, where he ran a healthcare fund focused on biotechnology, pharmaceutical, and medical device companies. Before joining Millennium, Dr. Hack was a healthcare analyst at HealthCor Management, L.P., a registered investment advisor. Previously, he served as a healthcare analyst for hedge fund Carlyle-Blue Wave Partners and as principal of the MPM BioEquities Fund, a hedge fund that was affiliated with MPM Capital. Earlier in his career, Dr. Hack was Director of Life Sciences and co-founder of Reify Corporation, a life science tools and drug discovery company. Dr. Hack serves as a director of Allena Pharmaceuticals, Inc. and Mersana Therapeutics, Inc. He received his B.A. in biology with special honors from the University of Chicago, where he also received his M.D. and Ph.D.
Daniel L. Kisner, M.D.
Dr. Kisner has been a member of the Dynavax board since July 2010. He most recently served as a partner at Aberdare Ventures and prior to that as President and CEO of Caliper Technologies, leading its evolution from a start-up focused on microfluidic lab-on-chip technology to a publicly traded, commercial organization. Prior to Caliper, he was the President and Chief Operating Officer of Isis Pharmaceuticals, Inc., a biomedical pharmaceutical company. Previously, Dr. Kisner was Division Vice President of Pharmaceutical Development for Abbott Laboratories and Vice President of Clinical Research and Development at SmithKline Beckman Pharmaceuticals. In addition, he held a tenured position in the Division of Oncology at the University of Texas, San Antonio School of Medicine and is certified by the American Board of Internal Medicine in Internal Medicine and Medical Oncology. Dr. Kisner serves on the Board of Directors of Conatus Pharmaceuticals, Inc. and Zynerba Pharmaceuticals, Inc. He holds a B.A. from Rutgers University and an M.D. from Georgetown University.
Peggy V. Phillips
Ms. Phillips has been a member of the Dynavax board since August 2006. Ms. Phillips currently also serves on the board of directors of Portola Pharmaceuticals, a biopharmaceutical company, and she served on the board of Western Wireless, a cellular network operator, from 2004 until the acquisition of the company by Alltel in mid-2005. From 2003 until 2011, Ms. Phillips served on the Board of the Naval Academy Foundation. From 1996 until 2002, she served on the board of directors of Immunex Corporation, a biotechnology company, and, from 1999, she served as the Chief Operating Officer until the company was acquired by Amgen in 2002. During her career at Immunex, she held positions of increasing responsibility in research, development, manufacturing, sales and marketing. As senior vice president for pharmaceutical development and general manager for Enbrel®, she was responsible for clinical development and regulatory affairs as well as the launch, sales and marketing of the product. Prior to joining Immunex, Ms. Phillips worked at Miles Laboratories. Ms. Phillips holds a B.S. and a M.S. in microbiology from the University of Idaho.
Natale (“Nat”) Ricciardi
Mr. Ricciardi was appointed to the Dynavax board in June 2013. Mr. Ricciardi spent his entire 39-year biopharmaceutical career at Pfizer Inc, retiring in 2011 as a member of the Pfizer Executive Leadership Team. While holding the positions of President, Pfizer Global Manufacturing, and Senior Vice President of Pfizer Inc, Nat was directly responsible for all of Pfizer's internal and external supply organization, a global enterprise that grew to more than 100 manufacturing facilities supplying small and large molecule pharmaceuticals, vaccines, consumer, nutrition and animal health products. Mr. Ricciardi maintained responsibility for global manufacturing activities from 2004 through 2011. Previously, from 1999 to 2004, he had oversight for Pfizer's US manufacturing operations and from 1995 to 1999 was Vice President of Manufacturing for Pfizer's Animal Health Group. Mr. Ricciardi served on the boards of the National Association of Manufacturers and Mediacom Communications Corporation until its privatization in 2011. He is currently a member of the boards of Prestige Brands Holdings, Inc. and the 21st Century Foundation of The City College of New York. Nat earned a degree in Chemical Engineering from The City College of New York and an MBA in Finance and International Business from Fordham University.
Dynavax GmbH (Dynavax Europe), is the European affiliate of Dynavax Technologies Corporation. For more than 25 years, we have been dedicated to the development and manufacturing of vaccines and biopharmaceuticals.